Amiodarone Usage After Ischemic Ventricular Tachycardia Ablation

Ventricular Tachycardia Clinical Trial

Official title:

Effect of Amiodarone After Ischemic Ventricular Tachycardia Ablation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03244748
• Other study ID #: ozcan01
• Status: Recruiting
• Phase: N/A
• First received: August 5, 2017
• Last updated: August 5, 2017
• Start date: January 1, 2016
• Est. completion date: March 1, 2018

Study information

• Verified date: August 2017
• Source: Yuksek Ihtisas Hospital
• Contact: Firat Ozcan, Ass. Prof, MD
• Phone: +905327854000
• Email: drfozcan[@]gmail.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Ventricular Tachycardia ablation in ischemic cardiomyopathy patients is required procedure in cases when anti-arrhythmic drugs failed. The concern is if adjunctive continuation amiodarone after ablation is needed.

Description:

Ischemic cardiomyopathy patients have implantable cardioverter defibrillators (ICD) to prevent arrhythmic deaths. Ventricular tachycardia (VT) events with frequent ICD interventions in ischemic cardiomyopathy patients is encountered frequently. Frequents ICD interventions is associated with worse outcomes. Anti-arrhythmic drugs ,mostly amiodarone, are given prevent ventricular arrhythmias and ICD interventions that may not be curative. Ablation of ventricular tachycardia is the suggested treatment when anti-drugs are without effect. After ablation of ventricular arrhythmia the continuation of amiodarone is not well elucidated.

In this study we aimed to enroll ischemic cardiomyopathy patients having frequent ICD interventions despite medical treatment. VT ablation is performed and patients divided into two groups; group one continues having amiodarone after ablation, group two does not have amiodarone after ablation. Both groups will be compared in terms of recurrence and death.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: March 1, 2018
• Est. primary completion date: January 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Ischemic cardiomyopathy patients applied with frequent ICD interventionor electrical storms and having ejection fraction below 50%. Frequent ICD defined as more than 1 ICD intervention within month. Electrical storm defined as more than 2 ICD intervention within one day.

Exclusion Criteria:

Patients with cardiomyopathies other than ischemic etiology

Related Conditions & MeSH terms

• Cardiomyopathies
• ICD Shock
• Ischemia
• Ischemic Cardiomyopathy
• Tachycardia
• Tachycardia, Ventricular
• Ventricular Tachycardia

Intervention

Procedure:
• Ventricular tachycardia ablation
Electrophysiologic procedure aims to ablate and terminate arrhythmia percutaneously

Locations

Country	Name	City	State
Turkey	Turkiye Yuksek Ihtisas Training and Research Hospital	Ankara

Sponsors (1)

Lead Sponsor	Collaborator
Yuksek Ihtisas Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Major adverse cardiovascular events	Death, ICD intervetion	six months